CMMB
Chemomab Therapeutics Ltd.
Price Chart
Latest Quote
$1.52
+0.03 (+1.81%)
Current Price
| Previous Close | $1.49 |
| Open | $1.50 |
| Day High | $1.57 |
| Day Low | $1.50 |
| Volume | 62,089 |
Stock Information
| Shares Outstanding | 7.20M |
| Cash Equivalents | $8.04M |
| Net Income | $-7.45M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.94M |
| EPS (TTM) | $-1.12 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.77M |
| Income | $-7.45M |
| Book/sh | $1.49 |
| Cash/sh | $1.12 |
Financial Ratios
| Quick Ratio | 10.31 |
| Current Ratio | 10.31 |
Returns & Margins
| ROA | -40.25% |
| ROE | -70.61% |
Ownership
| Insider Ownership | 11.28% |
| Institutional Ownership | 4.88% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -50.67 |
| P/B | 1.02 |
Analyst Data
| Recommendation | none |
| Target Price | $15.00 |
Technical Indicators
| SMA20 | $1.78 |
| SMA50 | $1.71 |
| SMA200 | $2.12 |
| RSI | 25.26 |
| ATR | 0.1690 |
| Shares Float | 6.40M |
| Short Float | 0.55% |
| Short Ratio | 0.82 |
| Volatility | 0.61 |
| Rel Volume | 1.14 |
Performance History
| Week | -14.61% |
| Month | -1.94% |
| Quarter | -21.24% |
| 6 Months | -26.21% |
| YTD | -15.08% |
| Year | -68.33% |
| 3 Years | -78.53% |
| 5 Years | -98.41% |
| 10 Years | -99.78% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $nan | 62,089 |
| 2026-06-17 | $1.50 | 69,800 |
| 2026-06-16 | $1.64 | 23,500 |
| 2026-06-15 | $1.58 | 165,800 |
| 2026-06-12 | $1.65 | 64,000 |
| 2026-06-11 | $1.78 | 12,300 |
| 2026-06-10 | $1.75 | 10,300 |
| 2026-06-09 | $1.73 | 29,000 |
| 2026-06-08 | $1.81 | 11,400 |
| 2026-06-05 | $1.77 | 41,900 |
| 2026-06-04 | $1.80 | 31,700 |
| 2026-06-03 | $1.72 | 16,000 |
| 2026-06-02 | $1.74 | 69,400 |
| 2026-06-01 | $1.86 | 110,600 |
| 2026-05-29 | $2.00 | 71,600 |
| 2026-05-28 | $2.07 | 38,300 |
| 2026-05-27 | $1.90 | 30,800 |
| 2026-05-26 | $2.03 | 56,100 |
| 2026-05-22 | $2.02 | 90,100 |
| 2026-05-21 | $1.82 | 81,200 |
| 2026-05-20 | $1.66 | 22,000 |
| 2026-05-19 | $1.55 | 40,200 |
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
đ° Latest News
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Zacks âĸ 2025-10-23T14:27:00Z
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Zacks âĸ 2025-10-22T14:18:00Z
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Zacks âĸ 2025-10-17T15:52:00Z
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
Zacks âĸ 2025-10-16T15:14:00Z
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Zacks âĸ 2025-10-15T15:31:00Z
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Zacks âĸ 2025-10-14T15:24:00Z
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Zacks âĸ 2025-10-10T16:21:00Z
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Zacks âĸ 2025-10-10T14:27:00Z
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
Zacks âĸ 2025-10-08T15:18:00Z
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
Zacks âĸ 2025-10-08T15:15:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $9,567,000 | $14,739,000 | $25,459,000 | $28,533,000 |
| Rent Expense Supplemental | $60,000 | $50,000 | $81,000 | $24,000 |
| Net Non Operating Interest Income Expense | $572,000 | $794,000 | $1,238,000 | $353,000 |
| Operating Expense | $9,567,000 | $14,739,000 | $25,459,000 | $28,533,000 |
| General And Administrative Expense | $3,734,000 | $3,412,000 | $7,078,000 | $11,556,000 |
| Total Other Finance Cost | - | $-794,000 | $-1,238,000 | $-353,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Net Interest Income | $572,000 | $794,000 | $1,238,000 | $353,000 |
| Interest Income | $572,000 | $794,000 | $1,238,000 | - |
| Normalized Income | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Net Income From Continuing And Discontinued Operation | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Net Income Common Stockholders | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Net Income | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Net Income Including Noncontrolling Interests | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Net Income Continuous Operations | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Pretax Income | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-28,180,000 |
| Interest Income Non Operating | $572,000 | $794,000 | $1,238,000 | - |
| Operating Income | $-9,567,000 | $-14,739,000 | $-25,459,000 | $-28,533,000 |
| Per Share | ||||
| Diluted EPS | $-1.44 | $-3.44 | $-8.24 | $-9.68 |
| Basic EPS | $-1.44 | $-3.44 | $-8.24 | $-9.68 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-9,497,000 | $-14,686,000 | $-25,392,000 | $-28,475,000 |
| Reconciled Depreciation | $70,000 | $53,000 | $67,000 | $58,000 |
| EBITDA (Bullshit earnings) | $-9,497,000 | $-14,686,000 | $-25,392,000 | $-28,475,000 |
| EBIT | $-9,567,000 | $-14,739,000 | $-25,459,000 | $-28,533,000 |
| Diluted Average Shares | $6,377,846 | $4,058,122 | $2,937,486 | $2,844,866 |
| Basic Average Shares | $6,377,846 | $4,058,122 | $2,937,486 | $2,844,866 |
| Diluted NI Availto Com Stockholders | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Tax Provision | $0 | $0 | $0 | $-534,000 |
| Research And Development | $5,833,000 | $11,327,000 | $18,381,000 | $16,977,000 |
| Selling General And Administration | $3,734,000 | $3,412,000 | $7,078,000 | $11,556,000 |
| Other Gand A | $1,381,000 | $1,239,000 | $2,462,000 | $4,019,000 |
| Insurance And Claims | $499,000 | $538,000 | $648,000 | $1,084,000 |
| Rent And Landing Fees | $60,000 | $50,000 | $81,000 | $24,000 |
| Salaries And Wages | $1,794,000 | $1,585,000 | $3,887,000 | $6,429,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $12,320,000 | $13,523,000 | $16,988,980 | $36,209,000 |
| Total Assets | $13,812,000 | $16,964,000 | $22,151,000 | $43,063,000 |
| Total Non Current Assets | $387,000 | $924,000 | $1,254,000 | $1,327,000 |
| Non Current Prepaid Assets | $211,000 | $385,000 | $559,000 | $733,000 |
| Goodwill And Other Intangible Assets | $14,000 | $14,000 | $8,020 | $14,000 |
| Other Intangible Assets | $14,000 | $14,000 | $8,020 | $14,000 |
| Current Assets | $13,425,000 | $16,040,000 | $20,897,000 | $41,736,000 |
| Restricted Cash | $0 | $76,000 | $76,000 | $77,000 |
| Prepaid Assets | $2,864,000 | $1,435,000 | $748,000 | $1,307,000 |
| Receivables | $195,000 | $263,000 | $289,000 | $459,000 |
| Other Receivables | $195,000 | $263,000 | $289,000 | $459,000 |
| Cash Cash Equivalents And Short Term Investments | $10,366,000 | $14,266,000 | $19,784,000 | $39,893,000 |
| Cash And Cash Equivalents | $7,564,000 | $6,071,000 | $9,292,000 | $13,519,000 |
| Other Non Current Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $0 | $324,000 | $392,000 | $214,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $209,000 | $316,000 | $91,000 |
| Current Debt And Capital Lease Obligation | - | $115,000 | $76,000 | $123,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,478,000 | $3,427,000 | $5,154,000 | $6,840,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $209,000 | $316,000 | $91,000 |
| Current Liabilities | $1,478,000 | $3,218,000 | $4,838,000 | $6,749,000 |
| Payables And Accrued Expenses | $822,000 | $2,169,000 | $3,939,000 | $5,066,000 |
| Payables | $485,000 | $633,000 | $516,000 | $1,688,000 |
| Accounts Payable | $485,000 | $633,000 | $516,000 | $1,688,000 |
| Equity | ||||
| Common Stock Equity | $12,334,000 | $13,537,000 | $16,997,000 | $36,223,000 |
| Total Equity Gross Minority Interest | $12,334,000 | $13,537,000 | $16,997,000 | $36,223,000 |
| Stockholders Equity | $12,334,000 | $13,537,000 | $16,997,000 | $36,223,000 |
| Retained Earnings | $-111,618,000 | $-102,623,000 | $-88,678,000 | $-63,819,000 |
| Other | ||||
| Ordinary Shares Number | $575,381,320 | $377,132,220 | $284,094,700 | $220,996,240 |
| Share Issued | $575,381,320 | $377,132,220 | $284,094,700 | $232,636,700 |
| Tangible Book Value | $12,320,000 | $13,523,000 | $16,988,980 | $36,209,000 |
| Invested Capital | $12,334,000 | $13,537,000 | $16,997,000 | $36,223,000 |
| Working Capital | $11,947,000 | $12,822,000 | $16,059,000 | $34,987,000 |
| Capital Lease Obligations | $0 | $324,000 | $392,000 | $214,000 |
| Total Capitalization | $12,334,000 | $13,537,000 | $16,997,000 | $36,223,000 |
| Treasury Stock | $0 | $0 | $0 | $1,218,000 |
| Additional Paid In Capital | $123,952,000 | $116,160,000 | $105,675,000 | $101,260,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $209,000 | $316,000 | $91,000 |
| Current Capital Lease Obligation | $0 | $115,000 | $76,000 | $123,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $656,000 | $934,000 | $823,000 | $1,560,000 |
| Current Accrued Expenses | $337,000 | $1,536,000 | $3,423,000 | $3,378,000 |
| Net PPE | $162,000 | $525,000 | $686,980 | $580,000 |
| Accumulated Depreciation | $-311,000 | $-279,000 | $-220,020 | $-165,000 |
| Gross PPE | $473,000 | $804,000 | $907,000 | $745,000 |
| Leases | $0 | $14,000 | $14,000 | $16,000 |
| Other Properties | $397,000 | $689,000 | $792,000 | $626,000 |
| Machinery Furniture Equipment | $76,000 | $101,000 | $101,000 | $103,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $2,802,000 | $8,195,000 | $10,492,000 | $26,374,000 |
| Treasury Shares Number | - | - | $11,640,460 | $11,640,460 |
| Construction In Progress | - | - | $14,000 | $14,000 |
| Investments And Advances | - | - | - | - |
| Other Investments | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-11,133,000 | $-15,386,000 | $-23,614,000 | $-20,438,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-11,130,000 | $-15,386,000 | $-23,611,000 | $-20,370,000 |
| Cash Flow From Continuing Operating Activities | $-11,130,000 | $-15,386,000 | $-23,611,000 | $-20,370,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,000 | - | $-3,000 | $-68,000 |
| Investing Cash Flow | $5,390,000 | $2,297,000 | $15,879,000 | $19,533,000 |
| Cash Flow From Continuing Investing Activities | $5,390,000 | $2,297,000 | $15,879,000 | $19,533,000 |
| Net Other Investing Changes | $5,393,000 | $2,297,000 | $15,882,000 | $19,601,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $7,145,000 | $9,868,000 | $3,504,000 | $267,000 |
| Financing Cash Flow | $7,157,000 | $9,868,000 | $3,504,000 | $-808,000 |
| Cash Flow From Continuing Financing Activities | $7,157,000 | $9,868,000 | $3,504,000 | $-808,000 |
| Net Common Stock Issuance | $7,145,000 | $9,868,000 | $3,504,000 | $-951,000 |
| Common Stock Issuance | $7,145,000 | $9,868,000 | $3,504,000 | $267,000 |
| Repurchase Of Capital Stock | - | $0 | $0 | $-1,218,000 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| End Cash Position | $7,564,000 | $6,147,000 | $9,368,000 | $13,596,000 |
| Beginning Cash Position | $6,147,000 | $9,368,000 | $13,596,000 | $15,241,000 |
| Changes In Cash | $1,417,000 | $-3,221,000 | $-4,228,000 | $-1,645,000 |
| Proceeds From Stock Option Exercised | $12,000 | $0 | $0 | $143,000 |
| Net PPE Purchase And Sale | $-3,000 | $0 | $-3,000 | $-68,000 |
| Purchase Of PPE | $-3,000 | $0 | $-3,000 | $-68,000 |
| Change In Working Capital | $-2,835,000 | $-2,111,000 | $-948,000 | $4,007,000 |
| Change In Other Working Capital | $-313,000 | $146,000 | $-724,000 | $896,000 |
| Change In Payables And Accrued Expense | $-1,379,000 | $-1,770,000 | $-1,127,000 | $3,175,000 |
| Change In Accrued Expense | $-1,202,000 | $-1,887,000 | $45,000 | $2,823,000 |
| Change In Payable | $-177,000 | $117,000 | $-1,172,000 | $352,000 |
| Change In Account Payable | $-177,000 | $117,000 | $-1,172,000 | $352,000 |
| Change In Receivables | $-1,143,000 | $-487,000 | $903,000 | $-64,000 |
| Other Non Cash Items | $7,000 | - | - | - |
| Stock Based Compensation | $623,000 | $617,000 | $1,491,000 | $3,211,000 |
| Depreciation Amortization Depletion | $70,000 | $53,000 | $67,000 | $58,000 |
| Depreciation And Amortization | $70,000 | $53,000 | $67,000 | $58,000 |
| Depreciation | $70,000 | $53,000 | $67,000 | $58,000 |
| Net Income From Continuing Operations | $-8,995,000 | $-13,945,000 | $-24,221,000 | $-27,646,000 |
| Common Stock Payments | - | $0 | $0 | $-1,218,000 |
| Sale Of PPE | - | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | - | - | - | $5,000 |
| Net Investment Purchase And Sale | - | - | - | $19,601,000 |
| Sale Of Investment | - | - | - | $19,601,000 |
| Purchase Of Investment | - | - | - | - |
Fetched: 2026-06-17